The activation of FGFR1 signaling in prostate cancer cells (Krt4+ luminal cells in scRNA-Seq) with KLF5 deacetylation was suggested by GSEA utilizing RNA-Seq data from both AP and DP samples (Figure 3C), confirmed by the activation of FRS2, ERK, and AKT, three canonical downstream targets of FGFR1 (25) (Figure 3D), and further addressed by scRNA-Seq analysis (Figure 4). The gene discussed is FRS2; the disease is prostate carcinoma.